BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Dowpharma (DOW) Consolidates Biopharmaceutical Process Development To San Diego


10/19/2005 5:11:29 PM

Dowpharma, a business unit of The Dow Chemical Company, will consolidate its biopharmaceutical customer process development activities to Dow's Research & Development (R&D) biotechnology site located in San Diego, Calif. Process development activities from Dowpharma's Stony Brook, N.Y. facility will now be integrated into the San Diego facility. The San Diego site, located in a regional biotech hub, will focus on the rapid process development and scale-up of client production processes for therapeutic proteins and peptides expressed in various systems. "The cutting-edge work at San Diego is exemplified by the development and recent launch of PROTEIN FACTORY, a novel Pseudomonas fluorescens based expression technology from Dowpharma, for the production of therapeutic proteins and peptides," says Nick Hyde, business director, Dowpharma. "Integrating all of our biopharmaceutical customer process development activities will allow us to leverage the significant resources and expertise that exist within Dow's biotechnology R&D. It will enable us to offer our customers state-of-the-art capabilities. Dowpharma is committed to becoming a leader in biopharmaceutical contract manufacturing and will continue to invest in opportunities that will allow us to help make affordable medicines for our customers," states Hyde.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES